X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs SUVEN LIFESCIENCES - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA SUVEN LIFESCIENCES SUN PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 32.3 18.4 175.7% View Chart
P/BV x 2.7 3.3 81.3% View Chart
Dividend Yield % 0.5 0.6 73.7%  

Financials

 SUN PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-19
SUN PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs701338 207.4%   
Low Rs433169 255.7%   
Sales per share (Unadj.) Rs110.452.1 211.8%  
Earnings per share (Unadj.) Rs11.06.8 160.7%  
Cash flow per share (Unadj.) Rs17.28.6 201.0%  
Dividends per share (Unadj.) Rs2.001.50 133.3%  
Dividend yield (eoy) %0.40.6 59.6%  
Book value per share (Unadj.) Rs158.865.3 243.2%  
Shares outstanding (eoy) m2,399.26127.28 1,885.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.9 105.6%   
Avg P/E ratio x51.637.1 139.1%  
P/CF ratio (eoy) x32.929.6 111.2%  
Price / Book Value ratio x3.63.9 91.9%  
Dividend payout %18.222.0 83.0%   
Avg Mkt Cap Rs m1,360,02132,272 4,214.3%   
No. of employees `00017.81.1 1,644.1%   
Total wages/salary Rs m53,671661 8,117.1%   
Avg. sales/employee Rs Th14,890.96,132.2 242.8%   
Avg. wages/employee Rs Th3,017.1611.1 493.7%   
Avg. net profit/employee Rs Th1,480.6803.5 184.3%   
INCOME DATA
Net Sales Rs m264,8956,635 3,992.4%  
Other income Rs m8,388242 3,461.8%   
Total revenues Rs m273,2826,877 3,973.7%   
Gross profit Rs m56,0811,604 3,495.9%  
Depreciation Rs m14,998221 6,774.3%   
Interest Rs m5,17638 13,728.6%   
Profit before tax Rs m44,2951,587 2,790.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452718 1,177.2%   
Profit after tax Rs m26,338869 3,029.4%  
Gross profit margin %21.224.2 87.6%  
Effective tax rate %19.145.2 42.2%   
Net profit margin %9.913.1 75.9%  
BALANCE SHEET DATA
Current assets Rs m316,3596,232 5,076.2%   
Current liabilities Rs m198,6431,490 13,330.9%   
Net working cap to sales %44.471.5 62.2%  
Current ratio x1.64.2 38.1%  
Inventory Days Days9586 109.7%  
Debtors Days Days10883 130.4%  
Net fixed assets Rs m213,1784,043 5,272.3%   
Share capital Rs m2,399127 1,884.8%   
"Free" reserves Rs m378,6068,183 4,626.9%   
Net worth Rs m381,0068,310 4,585.0%   
Long term debt Rs m17,72118 99,555.6%   
Total assets Rs m643,02810,389 6,189.6%  
Interest coverage x9.643.1 22.2%   
Debt to equity ratio x00 2,171.4%  
Sales to assets ratio x0.40.6 64.5%   
Return on assets %4.98.7 56.1%  
Return on equity %6.910.5 66.1%  
Return on capital %10.019.5 51.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,8165,622 726.0%   
Fx outflow Rs m30,1431,799 1,675.2%   
Net fx Rs m10,6733,822 279.2%   
CASH FLOW
From Operations Rs m39,072356 10,990.6%  
From Investments Rs m-33,708-279 12,099.1%  
From Financial Activity Rs m-15,393-225 6,838.1%  
Net Cashflow Rs m-7,359-148 4,965.7%  

Share Holding

Indian Promoters % 63.7 63.4 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 36.5 22.7%  
Shareholders   133,026 37,287 356.8%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   AUROBINDO PHARMA  DR. REDDYS LAB  IPCA LABS  CADILA HEALTHCARE  ALEMBIC LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; HDFC Bank and Yes Bank Top Gainers(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.2% while the Hang Seng is up 1%.

Related Views on News

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 24, 2019 11:49 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS